Jeffrey Stein, Cidara Therapeutics CEO

FDA ap­proves Cidara's Rez­za­yo as an­ti­fun­gal treat­ment for can­didemia and in­va­sive can­didi­a­sis

Cidara Ther­a­peu­tics’ an­ti­fun­gal Rez­za­yo (reza­fun­gin) has been ap­proved by the FDA un­der pri­or­i­ty re­view for the treat­ment of can­didemia and in­va­sive can­didi­a­sis in adults with lim­it­ed or no al­ter­na­tive treat­ment op­tions, the com­pa­ny an­nounced Wednes­day.

While the EMA ac­cept­ed the mar­ket­ing au­tho­riza­tion ap­pli­ca­tion for reza­fun­gin in Au­gust 2022, it is still un­der re­view for po­ten­tial ap­proval in Eu­rope.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.